42 results
8-K
EX-99.1
CCCC
C4 Therapeutics Inc
8 May 24
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
7:07am
was primarily due to the prioritization of our internal discovery efforts and stopping clinical development for CFT8634, partially offset by increased … of shares under our at the market (ATM) offering arrangement, both of which were previously disclosed. These inflows were partially offset by cash
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
carryforwards could expire unused and be unavailable to offset our future income tax liabilities. In addition, under Sections 382 and 383 of the Internal … - change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. In 2021, we
8-K
EX-99.1
rgesjq
22 Feb 24
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:15am
8-K
EX-99.1
sn6vpwtc92ast72fe
8 Aug 23
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
7:09am
ARS
4tqbdsp v8054
28 Apr 23
Annual report to shareholders
7:03am
8-K
EX-99.1
qodaivjdo
4 Aug 22
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8:15am
8-K
EX-99.1
3w3ln2z3kc6
24 Feb 22
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
7:30am
8-K
EX-99.1
vg5e z8el3gwt9lx6v
10 Nov 21
C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results
4:12pm